Sugammadex is associated with shorter hospital length of stay after open lobectomy for lung cancer: a retrospective observational study

Table 1 Demographic and clinical characteristics at baseline of matched cohort

Variable	Pyridostigmine (n = 127)	Sugammadex (n = 127)	p value
Age (year)	66.0 (59.5–71.0)	67.0 (60.0–72.0)	0.358
Male sex	92 (72.4)	96 (75.6)	0.668
Height (cm)	163.0 (159.0–168.5)	163.0 (158.0–168.0)	0.640
Weight (kg)	62.0 (56.0–67.0)	61.0 (56.0–69.5)	0.817
BMI (kg m⁻²)	23.1 (21.5–25.5)	23.5 (21.3–25.7)	0.445
ASA PS			0.238
I	14 (11.0)	19 (15.0)
II	104 (81.9)	93 (73.2)
III	9 (7.1)	15 (11.8)
Diabetes mellitus	22 (17.3)	27 (21.3)	0.525
Hypertension	55 (43.3)	55 (43.3)	1.000
CKD	5 (3.9)	2 (1.6)	0.443
Heart failure	3 (2.4)	0 (0.0)	0.245
CAD	14 (11.0)	12 (9.4)	0.836
COPD	28 (22.0)	31 (24.4)	0.766
Asthma	3 (2.4)	0 (0.0)	0.245
Operation site (right)	85 (66.9)	76 (59.8)	0.297

Data are presented as n (%), median (interquartile range)
BMI Body mass index, ASA PS American Society of Anesthesiologists physical status, CKD Chronic kidney disease, CAD Coronary arterial disease, COPD Chronic obstructive pulmonary disease

ISSN: 1749-8090